Does Vandetanib work well?

In a major study, vandetanib was more effective in adults with medullary thyroid cancer that cannot be removed with surgery or has spread to other parts of the body. The study involved 331 patients, and on average, those taking vandetanib lived 30.5 months without worsening of their disease. In the second major study, vandetanib was given to children aged 9 to 17 years with hereditary medullary thyroid cancer, which took into account several characteristics of the disease. Among children treated with vandetanib, 44% had a partial response on the ORR scale, which is comparable to response rates in adults. Children taking vandetanib survived an average of 46 months without disease progression.